SINGAPORE] Private equity (PE) players have seen the lack of exit opportunities in the first half of 2025 contribute to a decline in private dealmaking. A revival in initial public offerings (IPOs) ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The $139 billion TAMP has hired industry veteran Phil Rogerson, unveils $10 million commitment for strategic expansion in ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...

The $139 billion TAMP has hired industry veteran Phil Rogerson, unveils $10 million commitment for strategic expansion in ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The increasing appeal of the German market was evidenced this week with the news that PE firm Bridgepoint is close to signing ...